Lyophilised Antibody Formulation
Anti-sclerostin antibodies are formulated as lyophilisates. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 25 mg/ml. The lyophilisate may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.
1 . A lyophilisate comprising an anti-sclerostin monoclonal antibody, wherein the lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 25 mg/ml.
2 . A lyophilisate comprising an anti-sclerostin monoclonal antibody, wherein the lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which less than 1% of the anti-sclerostin antibody is aggregated.
3 . A lyophilisate comprising: an anti-sclerostin monoclonal antibody; a sugar; a buffering agent; and a surfactant.
4 . The lyophilisate of claim 2 , further comprising a free amino acid.
5 . The lyophilisate of claim 1 , wherein the lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which less than 1% of the anti-sclerostin antibody is aggregated.
6 . The lyophilisate of claim 2 , wherein the lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 25 mg/ml.
7 . The lyophilisate of claim 2 , comprising one, two or three of: a sugar; a buffering agent; and a surfactant.
8 . The lyophilisate of claim 7 , further comprising a free amino acid.
9 . The lyophilisate of claim 1 , wherein the lyophilisates can be reconstituted to give an aqueous composition with an anti-sclerostin antibody concentration of at least 125 mg/ml.
10 . The lyophilisate of claim 1 , comprising sucrose.
11 . The lyophilisate of claim 10 , comprising 200-300 mM sucrose.
12 . The lyophilisate of claim 1 , comprising a histidine buffer.
13 . The lyophilisate of claim 12 , comprising 25-35 mM histidine buffer.
14 . The lyophilisate of claim 1 , comprising polysorbate 80.
15 . The lyophilisate of claim 14 , comprising 0.01 to 0.1% polysorbate 80.
16 . The lyophilisate of claim 1 , comprising arginine.
17 . The lyophilisate of claim 15 , comprising 40-80 mM arginine.
18 . The lyophilisate of claim 1 , comprising sucrose, a histidine buffer, polysorbate 80 and arginine.
19 . The lyophilisate of claim 1 , wherein the anti-sclerostin antibody includes: (i) one or more heavy chain CDRs selected from the group consisting of SEQ ID NOs: 3, 4 & 5; and/or (ii) one or more light chain CDRs selected from the group consisting of SEQ ID NOs: 6, 7 & 8.
20 . The lyophilisate of claim 1 , wherein the anti-sclerostin antibody has a V H domain with amino acid SEQ ID NO: 1 and/or a V L domain with amino acid SEQ ID NO: 2.
21 . An aqueous pharmaceutical composition obtainable by reconstitution of the lyophilisate of claim 1 with an aqueous reconstituent.
22 . A process for preparing the lyophilisate of claim 1 , wherein the process comprises the steps of: (i) preparing an aqueous solution comprising an anti-sclerostin monoclonal antibody, a sugar, a buffering agent, a surfactant, and, optionally, a free amino acid; and (ii) lyophilising the aqueous solution.
23 . A process for preparing a pharmaceutical composition, comprising a step of: mixing the lyophilisate of claim 1 with an aqueous reconstituent.
24 . A delivery device including the pharmaceutical composition of claim 21 .
25 . A method for delivering an anti-sclerostin monoclonal antibody to a mammal, comprising a step of administering to the patient a pharmaceutical composition of claim 21 .
26 . The composition of claim 21 for use in treating a disease or disorders in which bone mineral density is abnormally and/or pathologically high relative to healthy subjects.
27 . The composition of claim 21 for use in treating a disease or disorders in which bone mineral density is abnormally and/or pathologically low relative to healthy subjects.
28 . The composition of claim 21 for use in treating osteoporosis.